| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Craig W Spellma. Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients. The Journal of the American Osteopathic Association. vol 111. issue 2 Suppl 1. 2011-06-09. PMID:21389294. |
current us food and drug administration indications do not include the concomitant use of glp-1 agonists with insulin. |
2011-06-09 |
2023-08-12 |
Not clear |
| Stephanie M Gustavson, Haiqing Dai, Gregory M Preston, Veena Somayaji, Boaz Hirshberg, Roberto A Call. Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus. Diabetes research and clinical practice. vol 91. issue 2. 2011-06-08. PMID:21130513. |
a randomized, placebo-controlled study evaluated the effects multiple-doses (28 days) dipeptidyl peptidase-iv (dpp-iv) inhibitor pf-734200 on dpp-iv activity, glucose, glucagon-like peptide-1 (glp-1), glucagon and insulin levels in 72 subjects with type 2 diabetes. |
2011-06-08 |
2023-08-12 |
human |
| Antonio Ceriello, Katherine Esposito, Roberto Testa, Anna Rita Bonfigli, Maurizio Marra, Dario Giuglian. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes care. vol 34. issue 3. 2011-06-08. PMID:21273492. |
glucagon-like peptide 1 (glp-1) stimulates insulin secretion. |
2011-06-08 |
2023-08-12 |
Not clear |
| M R Rickels, A Naj. Reactive hypoglycaemia following GLP-1 infusion in pancreas transplant recipients. Diabetes, obesity & metabolism. vol 12. issue 8. 2011-06-02. PMID:20590751. |
the aim of the study was to determine whether reactive hypoglycaemia in pancreas transplant recipients that followed administration of glucagon-like peptide-1 (glp-1) was associated with excessive insulin, insufficient glucagon, or both. |
2011-06-02 |
2023-08-12 |
human |
| M R Rickels, A Naj. Reactive hypoglycaemia following GLP-1 infusion in pancreas transplant recipients. Diabetes, obesity & metabolism. vol 12. issue 8. 2011-06-02. PMID:20590751. |
during hypoglycaemia, insulin levels and the insulin-to-glucagon ratio were greater after glp-1 vs. placebo infusion (p < 0.05), while glucagon did not vary. |
2011-06-02 |
2023-08-12 |
human |
| M R Rickels, A Naj. Reactive hypoglycaemia following GLP-1 infusion in pancreas transplant recipients. Diabetes, obesity & metabolism. vol 12. issue 8. 2011-06-02. PMID:20590751. |
it can be concluded from the study that glp-1 can induce reactive hypoglycaemia in pancreas transplant recipients through excessive insulin secretion associated with an increased insulin-to-glucagon ratio. |
2011-06-02 |
2023-08-12 |
human |
| Meena Asma. New physiological effects of the incretin hormones GLP-1 and GIP. Danish medical bulletin. vol 58. issue 2. 2011-06-02. PMID:21299928. |
currently, it is not known whether the inhibiting effects of glp-1 on gastric emptying, appetite and food intake are directly mediated by glp-1, or if the effects are secondary to the robust insulin responses, and thereby amylin responses, elicited by glp-1. |
2011-06-02 |
2023-08-12 |
Not clear |
| Isabelle Bourdel-Marchasson, Anja Schweizer, Sylvie Dejage. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hospital practice (1995). vol 39. issue 1. 2011-06-02. PMID:21441754. |
incretins (glucose-dependent insulinotropic polypeptide [gip] and glucagon-like peptide-1 [glp-1]) are hormones released post-meal from intestinal endocrine cells that stimulate insulin secretion and suppress postprandial glucagon secretion in a glucose-dependent manner. |
2011-06-02 |
2023-08-12 |
Not clear |
| Ghinwa M Barakat, Nuha Nuwayri-Salti, Lina N Kadi, Khalil M Bitar, Wael A Al-Jaroudi, Anwar B Bikhaz. Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts. General physiology and biophysics. vol 30. issue 1. 2011-05-24. PMID:21460410. |
we studied the effects of insulin, glp-1 analogues (exendin-4), and dipeptidyl peptidase-iv (dpp-iv) inhibitor on glp-1 cardiac receptor modulation. |
2011-05-24 |
2023-08-12 |
rat |
| Abdelilah Arredouani, A Mark Evans, Jianjie Ma, John Parrington, Michael X Zhu, Antony Galion. An emerging role for NAADP-mediated Ca2+ signaling in the pancreatic β-cell. Islets. vol 2. issue 5. 2011-05-16. PMID:21099331. |
these studies have highlighted a role for naadp-induced ca(2+) mobilization not only in mediating the effects of the incretin, glp-1 and the autocrine proliferative effects of insulin, but also possibly a fundamental role in glucose-mediated insulin secretion in the pancreatic β-cell. |
2011-05-16 |
2023-08-12 |
Not clear |
| B Charbonnel, B Cario. Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes, obesity & metabolism. vol 13. issue 2. 2011-05-16. PMID:21199262. |
efficacy with metformin therapy is usually of limited duration, which necessitates the early introduction of one or two additional oral agents or the initiation of injections, glucagon-like peptide-1 (glp-1) agonists or insulin. |
2011-05-16 |
2023-08-12 |
human |
| A P Gjesing, L L Kjems, M A Vestmar, N Grarup, A Linneberg, C F Deacon, J J Holst, O Pedersen, T Hanse. Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test. Diabetologia. vol 54. issue 1. 2011-05-11. PMID:20957343. |
we aimed to study circulating levels of glucose, proinsulin, insulin, c-peptide, glucagon, glucagon-like peptide-1 (glp-1), glucagon-like peptide-2 (glp-2) and gastric inhibitory polypeptide (gip) among individuals carrying the high-risk rs7903146 tt genotype and low-risk cc genotype following a meal test. |
2011-05-11 |
2023-08-12 |
Not clear |
| Y M Cho, T J Kieffe. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia. vol 54. issue 2. 2011-05-02. PMID:21116606. |
moreover, they show that metformin enhances the expression of the genes encoding the receptors for both glp-1 and glucose-dependent insulinotropic polypeptide (gip) in mouse islets and also increases the effects of gip and glp-1 on insulin secretion from beta cells. |
2011-05-02 |
2023-08-12 |
mouse |
| Jay V Patankar, Prakash G Chandak, Sascha Obrowsky, Thomas Pfeifer, Clemens Diwoky, Andreas Uellen, Wolfgang Sattler, Rudolf Stollberger, Gerald Hoefler, Akos Heinemann, Michele Battle, Stephen Duncan, Dagmar Kratky, Sanja Levak-Fran. Loss of intestinal GATA4 prevents diet-induced obesity and promotes insulin sensitivity in mice. American journal of physiology. Endocrinology and metabolism. vol 300. issue 3. 2011-04-22. PMID:21177287. |
in addition, we show that increased glp-1 release in gata4iko mice decreases the risk for development of insulin resistance. |
2011-04-22 |
2023-08-12 |
mouse |
| Shuchita Singh, Subhasis Roy, Sachin Sethi, Biju Benjamin, Sindhuja Sundaram, Vivek Khanna, Sachin R Kandalkar, Chanchal Pal, Rajiv Kant, Ashok Kumar Patra, Geetavani Rayasam, Shivani Mittra, Kulvinder Singh Saini, Jyoti Paliwal, Anita Chugh, Shahadat Ahmed, Jitendra Sattigeri, Ian Cliff, Abhijit Ray, Vinay S Bansal, Pradip Kumar Bhatnagar, Joseph Alex Davi. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. European journal of pharmacology. vol 652. issue 1-3. 2011-04-18. PMID:20540938. |
rbx-0597 (10mg/kg) showed a significant glucose lowering effect (∼25% auc of △ blood glucose) which was sustained till 12h, significantly increased the active glucagon-like peptide-1(glp-1) and insulin levels. |
2011-04-18 |
2023-08-12 |
mouse |
| Minglin Pan, Guang Yang, Xiuli Cui, Shao-Nian Yan. Subthreshold α₂-adrenergic activation counteracts glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion. Experimental diabetes research. vol 2011. 2011-04-18. PMID:21253359. |
the pancreatic β cell harbors α₂-adrenergic and glucagon-like peptide-1 (glp-1) receptors on its plasma membrane to sense the corresponding ligands adrenaline/noradrenaline and glp-1 to govern glucose-stimulated insulin secretion. |
2011-04-18 |
2023-08-12 |
Not clear |
| Minglin Pan, Guang Yang, Xiuli Cui, Shao-Nian Yan. Subthreshold α₂-adrenergic activation counteracts glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion. Experimental diabetes research. vol 2011. 2011-04-18. PMID:21253359. |
on the contrary, glp-1 concentration-dependently potentiates insulin secretory response to glucose. |
2011-04-18 |
2023-08-12 |
Not clear |
| Minglin Pan, Guang Yang, Xiuli Cui, Shao-Nian Yan. Subthreshold α₂-adrenergic activation counteracts glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion. Experimental diabetes research. vol 2011. 2011-04-18. PMID:21253359. |
importantly, the present work reveals that subthreshold α₂-adrenergic activation with clonidine counteracts glp-1 potentiation of glucose-induced insulin secretion. |
2011-04-18 |
2023-08-12 |
Not clear |
| Minglin Pan, Guang Yang, Xiuli Cui, Shao-Nian Yan. Subthreshold α₂-adrenergic activation counteracts glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion. Experimental diabetes research. vol 2011. 2011-04-18. PMID:21253359. |
the counteraction of glp-1 potentiation of glucose-stimulated insulin secretion by subthreshold α₂-adrenergic activation is likely to serve as a molecular mechanism for the delicate regulation of insulin release. |
2011-04-18 |
2023-08-12 |
Not clear |
| R Lupi, S Del Guerra, V D'Aleo, U Boggi, F Filipponi, P Marchett. The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets. Regulatory peptides. vol 165. issue 2-3. 2011-04-14. PMID:20472004. |
acutely, both glp-1 and, more markedly so, gip, significantly potentiated glucose-stimulated insulin release, with no apparent synergic action. |
2011-04-14 |
2023-08-12 |
human |